Associated tags: CGM, Skin, Health, Diabetes, Medical Devices, SENS, Health Technology, NYSE, Pharmaceutical industry, Medical device, Patient, Doctor of Philosophy
Health,
Technology,
Diabetes,
Health Technology,
Managed Care,
Software,
Consensus,
American Diabetes Association,
Physician,
Electronic health record,
RPM,
Safety,
Blood pressure,
EHR,
CGM,
Partnership,
Doctor of Philosophy,
Type 2 diabetes,
Patient,
Practitioner,
Remote patient monitoring,
Medical device Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.
Key Points:
- Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.
- “The Eversense RPM Program™ is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution.
- Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
- A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference, being held in New York, NY.
Key Points:
- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference, being held in New York, NY.
- Management is scheduled to participate in the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35pm ET and will hold one-on-one meetings.
- Management is scheduled to participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 4:00pm ET and will hold one-on-one meetings.
Software,
General Health,
Health,
Diabetes,
Medical Devices,
Health Technology,
Technology,
Apps,
Applications,
CGM,
International,
Publication,
Webcast,
Eastern Time Zone Management will hold a conference call to review the Company’s first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day.
Key Points:
- Management will hold a conference call to review the Company’s first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day.
- The conference call will be concurrently webcast.
- The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference.
- To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 7182212, approximately ten to five minutes prior to start time.
Health,
FDA,
Diabetes,
Medical Devices,
Health Technology,
Technology,
Apps,
Applications,
Mobile,
Wireless,
Consensus,
American Diabetes Association,
Safety,
Physician,
De novo,
CGM,
Partnership,
Doctor of Philosophy,
Patient,
Practitioner,
AID,
Medical device iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
Key Points:
- iCGM status indicates that Senseonics’ Eversense iCGM product can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
- “The rigorous data requirements for this FDA designation highlight our team's advanced engineering expertise in developing a CGM that meets high standards.
- Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
- Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
Health,
Medical Devices,
Diabetes,
Health Technology,
General Health,
Research,
Science,
T2D,
CGM,
Conference,
Fortezza,
Patient,
T1D,
Medical device Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”) in Florence, Italy.
Key Points:
- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is to be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”) in Florence, Italy.
- We are pleased the data shows high satisfaction scores, improved diabetes distress scores, and no evidence that repeated insertions and removals impact satisfaction,” said Francine Kaufman, M.D., Chief Medical Officer of Senseonics.
- “As patients and providers consider the best options to help manage diabetes, presenting this additional compelling data continues to raise the awareness of the benefits of Eversense.
- The DDS-17 (a questionnaire designed to measure four critical dimensions of distress with diabetes: emotional burden, regimen distress, interpersonal distress and physician distress) was administered to participants at the start of the study.
Health,
Communications,
Medical Devices,
Diabetes,
Health Technology,
General Health,
Public Relations,
Investor Relations,
Interest,
CGM,
Medtech,
Conference Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
Key Points:
- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.
- Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following.
- Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .
Retrieved on:
Thursday, February 29, 2024
Diabetes,
Health,
Medical Devices,
Total,
Research,
CGM,
Doctor of Philosophy,
Investment,
Telephone,
Marketing,
FDA,
Growth,
PHC,
Conference,
Medicare,
Patient,
Data analysis,
Acceleration,
Clinical trial,
Eastern Time Zone,
UnitedHealth Group,
Pharmaceutical industry U.S. revenue was $6.1 million in the fourth quarter of 2023 compared to $3.6 million in the prior year period, and revenue outside the U.S. was $1.9 million in the fourth quarter of 2023 compared to $2.0 million in the prior year period.
Key Points:
- U.S. revenue was $6.1 million in the fourth quarter of 2023 compared to $3.6 million in the prior year period, and revenue outside the U.S. was $1.9 million in the fourth quarter of 2023 compared to $2.0 million in the prior year period.
- Fourth quarter 2023 gross profit of $1.1 million increased from $0.6 million for the fourth quarter of 2022.
- Fourth quarter 2023 sales and marketing and general and administrative expenses decreased by $0.5 million year-over-year, to $7.3 million.
- Fourth quarter 2023 research and development expenses decreased by $0.9 million year-over-year, to $10.7 million.
Retrieved on:
Thursday, February 15, 2024
Management will hold a conference call to review the Company’s fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
Key Points:
- Management will hold a conference call to review the Company’s fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
- The conference call will be concurrently webcast.
- The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference.
- To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 3711982, approximately ten to five minutes prior to start time.
Retrieved on:
Monday, February 12, 2024
Software,
Mobile,
Wireless,
Professional Services,
Consumer Electronics,
Apps,
Applications,
Medical Devices,
Technology,
Health Technology,
Health Insurance,
Insurance,
Health,
Diabetes,
Blood glucose monitoring,
MAC,
CGM,
Macs,
Himawari (satellites),
NGS,
Practitioner,
History,
Patient,
Policy,
Insulin,
LCD,
Physician,
BGM,
Pharmaceutical industry Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
Key Points:
- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
- Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
- Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
- Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.
Retrieved on:
Tuesday, February 6, 2024
Diabetes,
Medical Devices,
Health,
Apps,
Applications,
Technology,
Partnership,
Growth,
Tandem Diabetes Care,
CGM,
BGM,
PHC,
Patient,
Longevity,
Thermo Fisher Scientific,
University,
Pharmaceutical industry PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
Key Points:
- PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
- Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
- Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets.
- The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care.
